Author: Cheryl Stratos
-
What Is Skin Cancer? What Is Melanoma?
Melanoma is a malignant tumor of melanocytes. The tumors are generally found in the skin, but may also appear in the bowel and the eye (uveal melanoma). Melanoma is a type of skin cancer – one of the rarer types – but the cause of most skin cancer related deaths. Malignant melanoma is caused by…
-
Best Cancer Hospitals – US News & World Reports
Compare the best cancer hospitals. U.S. News evaluated nearly 886 hospitals for cancer treatment and ranked the top 50 that treat cancers such as leukemia, lymphoma, melanoma, breast, kidney, colon, prostate, pancreatic, head and neck, orthopedic, uterine and ovarian cancers. See also a list of oncologists and hospitals that are high performing in colon cancer surgery, https://health.usnews.com/best-hospitals/hospital-ratings/lung-cancer-surgery”,”_type”:”d82f1fd9-c1d7-315a-9519-34a46b1f526f”},”_type”:”809caec9-30e2-3666-8b71-b32ddbffc288″}”>lung cancer surgery, https://health.usnews.com/best-hospitals/hospital-ratings/prostate-cancer-surgery”,”_type”:”d82f1fd9-c1d7-315a-9519-34a46b1f526f”},”_type”:”809caec9-30e2-3666-8b71-b32ddbffc288″}”>prostate…
-
New Melanoma Treatment Might Delay Cancer Progression
SATURDAY, Sept. 29 (HealthDay News) — Researchers say they’ve discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma. By targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said. Melanoma…
-
Glaxo Two-Drug Melanoma Combo Slows Cancer in Study
GlaxoSmithKline Plc (GSK)’s combination of two experimental melanoma medicines slowed the cancer’s progress longer than a single-drug treatment, a study found. Patients taking Glaxo’s dabrafenib and trametinib together delayed tumors from progressing for 9.4 months, compared with 5.8 months for patients taking dabrafenib alone, according to the study of 162 patients. The trial was part…
-
-
Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN-γ Enhances Anticancer Responses of Cell Products for Infusion
Further development of adoptive T-cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has the potential to markedly change the long-term prognosis of patients with metastatic melanoma, and modifications of the original protocol that can improve its clinical efficacy are highly desirable. In this study, we demonstrated that a high in vitro tumor reactivity of infusion…
-
Engineering the Immune System to Fight Melanoma
ScienceDaily (Oct. 1, 2012) — Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient’s immune system to fight the deadly cancer. A batch of the immune system’s killer T cells will be removed from the patient and genetically modified in a…
-
Exelixis: First Partnered Program Enters Phase III
Roche recently disclosed a decision to start phase III with GDC-0973 (formerly XL518), a MEK inhibitor licensed from Exelixis (EXEL) to Genentech 6 years ago. The trial is expected to start next month, and will evaluate GDC-0973 in combination with Roche’s Zelboraf in patients with BRAF-mutated melanoma. This is an extremely positive catalyst for Exelixis,…
-
Study confirms link between indoor tanning and skin cancer risk
Indoor tanning increases the risks of developing non-melanoma skin cancer (known as basal cell carcinoma and squamous cell carcinoma), particularly among those exposed before the age of 25, finds a study published on bmj.com today. It follows a BMJ study published in July that showed 3,438 (5.4%) new cases of melanoma diagnosed each year in…
-
ESMO: BRAF/MEK Inhibitor Combo Bests Monotherapy for Metastatic Melanoma
Phase II results presented at the European Society for Medical Oncology (ESMO) 2012 Congress showed a 3.6-month improvement in progression-free survival (PFS) for patients receiving both the BRAF inhibitor dabrafenib and trametinib, a MEK inhibitor, compared to those receiving dabrafenib alone. PFS was 9.4 months for patients who received dabrafenib plus trametinib compared to 5.8…